Chicken geeft vol gas! schreef op 9 november 2015 19:41:
Amgen is jumping back into the M&A game. And it's looking for another Onyx-sized deal that can deliver a late-stage drug ready to be hustled across the finish line.
The Financial Times reported this morning that Amgen's ($AMGN) management team has been briefing investors about its plans to buy another biotech for about $10 billion.